Given that we know that the sensitivity of p53 immunohistochemistry in detection of TP53 mutation is not 100% (see earlier), there will be a small percentage of morphologically prototypical endometrial serous carcinomas that exhibit a wild-type pattern of p53 immunoreactivity but still harbor a TP53 mutation (eg, truncating), and the diagnosis of serous carcinoma can be made in a tumor with wild-type p53 staining. Here, TP53 is linked to neoplasm.